Atorvastatin cuts anthracycline heart failure

Published Date: 08 Mar 2023

Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.

Read Full News

Latest News

Benefits of TrumpRx Drug Site Are Limited, Experts Say

A new federal prescription drug site promises to save patients money on popular drugs. Here’s what physicians should know about TrumpRx.

Mediterranean Diet May Lower All-Type Stroke Risk in Women

Results of a large cohort study show adherence to a Mediterranean diet is linked to a lower risk for all stroke types in women.

HIV & Menopause: A Combo We’re Just Beginning to Understand

As patients with HIV live longer, menopause is becoming routine, but the science, safety data, and responsibility for managing it are still catching up.

Mortality Up for Medicare Beneficiaries During Late COVID-19

Medicare beneficiaries with cardiovascular disease or risk factors had increased mortality rates and fewer hospitalizations in the later stages of the COVID-19 pandemic.

Early Findings on Implantable Device Look Promising

The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.

Should Prenatal Growth Restriction Inform Adult Screening?

Fetal growth restriction and extreme prematurity alter cardiovascular and pulmonary trajectories, with effects that persist from infancy into adult life.

Todays Updates

Improving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches

Improving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches

Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer

Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer

Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer

Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer

Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer

Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer

Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer

Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer

Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly

Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly

Navigating Advances in Cystic Fibrosis Care

Navigating Advances in Cystic Fibrosis Care

Todays Updates

Improving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches

Improving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches

Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer

Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer

Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer

Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer

Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer

Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer

Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer

Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer

Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly

Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly

Navigating Advances in Cystic Fibrosis Care

Navigating Advances in Cystic Fibrosis Care

Latest News

A new federal prescription drug site promises to save patients money on popular drugs. Here’s what physicians should know about TrumpRx.

Results of a large cohort study show adherence to a Mediterranean diet is linked to a lower risk for all stroke types in women.

As patients with HIV live longer, menopause is becoming routine, but the science, safety data, and responsibility for managing it are still catching up.

Medicare beneficiaries with cardiovascular disease or risk factors had increased mortality rates and fewer hospitalizations in the later stages of the COVID-19 pandemic.

The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.

Fetal growth restriction and extreme prematurity alter cardiovascular and pulmonary trajectories, with effects that persist from infancy into adult life.

News All Time

Imaging in Athletes: From Emergencies to Prevention

Beyond bones and muscles, imaging evaluates peripheral nerve injuries from compression to laceration; amateurs may be at higher risk due to poor technique and limited rehab access.

Cutaneous Oncology Updates for 2026, With Paul Nghiem, MD, PhD Paul Nghiem, MD, PhD

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

Discussing Billing Challenges in Dermatology, With Daniel Siegel, MD Daniel M. Siegel, MD

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

New Phase 3 Findings Support Ameluz-PDT for Patients with Actinic Keratosis

New Phase 3 Findings Support Ameluz-PDT for Patients with Actinic Keratosis

HCPLive 5 Stories in Under 5: Week of 02/01

HCPLive 5 Stories in Under 5: Week of 02/01

The HCPFive: Top News for Healthcare Providers from the Week of 02/01

The HCPFive: Top News for Healthcare Providers from the Week of 02/01

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD Henry Lim, MD

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

The Medical Sisterhood: Advocacy and Systemic Change, With Kristi Hawley, DO Mona Shahriari, MD, FAAD, Kristi B. Hawley, DO

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

Upadacitinib Safe for Atopic Dermatitis up to 7 Years in Pooled Analysis Findings

Upadacitinib Safe for Atopic Dermatitis up to 7 Years in Pooled Analysis Findings

Recommended News For You

Even when they are not paying attention, children are still learning.

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

According to new studies, some cancer patients can safely forego radiation therapy.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

How cancer misinformation exploits the way we think

New research demonstrates a method for screening people at high risk for pancreatic cancer.

A radiotheranostic approach designed to combat aggressive cancers

Recommended Articles For You

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options 

Recombinant ADAMTS13: Advancing Prophylaxis in Congenital TTP Management 

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control 

Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Independent Risk Factors for "Deaths of Despair" Found.

2.

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.

3.

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

4.

Researchers find distinct cell receptors with the potential for new treatments.

5.

Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.

1.

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis

2.

Cancer Rates on the Rise: What Can We Do to Stop It?

3.

AI on the Front Lines: Revolutionizing Breast Cancer Detection with Artificial Intelligence

4.

Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025

5.

Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

5.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot